| Literature DB >> 24900269 |
Kevin K-C Liu1, JinJiang Zhu1, Graham L Smith1, Min-Jean Yin1, Simon Bailey1, Jeffrey H Chen1, Qiyue Hu1, Qinhua Huang1, Chunze Li1, Qing J Li1, Matthew A Marx1, Genevieve Paderes1, Paul F Richardson1, Neal W Sach1, Marlena Walls1, Peter A Wells1, Sangita Baxi, Aihua Zou1.
Abstract
Highly selective PI3K inhibitors with subnanomolar PI3Kα potency and greater than 7000-fold selectivity against mTOR kinase were discovered through structure-based drug design (SBDD). These tetra-substituted thiophenes were also demonstrated to have good in vitro cellular potency and good in vivo oral antitumor activity in a mouse PI3K driven NCI-H1975 xenograft tumor model. Compounds with the desired human PK predictions and good in vitro ADMET properties were also identified. In this communication, we describe the rationale behind the installation of a critical triazole moiety to maintain the intricate H-bonding network within the PI3K receptor leading to both better potency and selectivity. Furthermore, optimization of the C-4 phenyl group was exploited to maximize the compounds mTOR selectivity.Entities:
Keywords: Kinase inhibitor; PI3K; antitumor activity; mTOR; thiophene; triazole
Year: 2011 PMID: 24900269 PMCID: PMC4018126 DOI: 10.1021/ml200126j
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345